Please wait

Exhibit 107

Calculation of Filing Fee Tables

424(b)(5)

(Form Type)

Krystal Biotech, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

 

                         
     Security
Type
 

Security
Class

Title

  Fee
Calculation
or Carry
Forward
Rule
  Amount
Registered
 

Proposed
Maximum
Offering
Price Per

Unit

 

Maximum
Aggregate
Offering

Price

 

Fee

Rate

  Amount of
Registration
Fee
 

Carry
Forward

Form
Type

 

Carry

Forward

File

Number

  Carry
Forward
Initial
Effective
Date
  Filing Fee
Previously
Paid in
Connection
with Unsold
Securities to
Be Carried
Forward
 
Newly Registered Securities
                         

Fees to Be

Paid

  Equity   Common Stock, par value $0.00001 per share   457(o)       $150,000,000   0.0001102   $16,530          
 
Carry Forward Securities
                         

Carry

Forward

Securities

  —     —     —     —     —     —     —     —            
                   
    Total Offering Amounts      $150,000,000     $16,530.00          
                   
    Total Fees Previously Paid                   
                   
    Total Fee Offsets          $11,182.75          
                   
    Net Fee Due                $5,347.25                


Table 2: Fee Offset Claims and Sources

 

                       
     Registrant
or Filer
Name
 

Form

or

Filing

Type

 

File

Number

 

Initial

Filing

Date

 

Filing

Date

  Fee Offset
Claimed
  Security
Type
Associated
with Fee
Offset
Claimed
  Security
Title
Associated
with Fee
Offset
Claimed
  Unsold
Securities
Associated
with Fee
Offset
Claimed
 

Unsold

Aggregate
Offering

Amount
Associated

with Fee

Offset

Claimed

 

Fee Paid

with Fee

Offset

Source

 
Rule 457(p)
                       
Fee Offset Claim   Krystal Biotech, Inc.   424(b)(5)   333-237983   December 31, 2020     $11,182.75(2)   Equity   Common Stock, $0.00001 par value per share (3)   —     $102,500,000    
                       
Fee Offset Sources   Krystal Biotech, Inc.   424(b)(5)   333-237983       December 31, 2020                       $11,182.75(2)

 

(1)

In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended (the “Securities Act”), the registrant initially deferred payment of all of the registration fees for the Registration Statement on Form S-3 (Registration No. 333-271167), filed on April 6, 2023.

(2)

On December 31, 2020, the registrant filed a prospectus supplement (the “2020 Prospectus Supplement”) to the prospectus included in its Registration Statement on Form S-3 (Registration Statement No. 333-237983) (the “2020 Registration Statement”) and concurrently submitted a fee of $16,365. The 2020 Prospectus Supplement related to the registrant’s offer and sale from time to time of shares of the registrant’s common stock, par value $0.00001 per share, having an aggregate gross sales price of up to $150,000,000 from time to time under an at-the-market program. As of the date of this prospectus supplement, $102,500,000 remains unsold under the at-the-market program. The 2020 Registration Statement and the offering that included the unsold securities under the 2020 Prospectus Supplement have been terminated. Pursuant to Rule 457(p) under the Securities Act, a registration fee credit of $11,182.75 is available to offset the current registration fee.